HTG Molecular Diagnostics, Inc. (HTGM) |
|
0.8821 -0.793 (-47.34%)
|
06-06 14:57 |
|
Open: |
0.91 |
Pre. Close: |
1.675 |
|
High:
|
1.13 |
Low:
|
0.86 |
|
Volume:
|
927,415 |
Market Cap:
|
2(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 2:18:42 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 2.72  One year: 3.78 |
| Support: |
Support1: 0.86 Support2: 0.71 |
| Resistance: |
Resistance1: 2.33 Resistance2: 3.24 |
| Pivot: |
2.28 |
| Moving Average: |
MA(5): 1.79 MA(20): 2.36
MA(100): 3.25 MA(250): 6.53 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 7 %D(3): 11.4 |
| RSI: |
RSI(14): 19.5 |
| 52-week: |
High: 24.95 Low: 0.86 |
| Average Vol(K): |
3-Month: 208 (K) 10-Days: 168 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HTGM ] has closed below the lower bollinger band by 20.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ HTGM ] is to continue within current trading range. It is unclear right now based on current values. 41.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.25 - 2.27 |
2.27 - 2.28 |
|
Low:
|
1.52 - 1.53 |
1.53 - 1.54 |
|
Close:
|
1.66 - 1.68 |
1.68 - 1.7 |
|
Company Description |
|
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. |
Headline News |
Tue, 06 Jun 2023
Should You Sell HTG Molecular Diagnostics Inc (HTGM) in Diagnostics & Research Industry? - InvestorsObserver
Tue, 06 Jun 2023
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here ... - Investing.com UK
Thu, 18 May 2023
HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention - Yahoo Finance
Wed, 10 May 2023
HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights - Yahoo Finance
Tue, 25 Apr 2023
HTG Provides Update on Drug Discovery Partnering Initiative - Yahoo Finance
Wed, 19 Apr 2023
HC Wainwright & Co. Reiterates HTG Molecular Diagnostics (HTGM ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
2 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
6.5 (%) |
|
% Held by Institutions
|
0.7 (%) |
|
Shares Short
|
58 (K) |
|
Shares Short P.Month
|
58 (K) |
Stock Financials |
|
EPS
|
-16.75 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.2 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-315.3 |
|
Return on Assets (ttm)
|
-62.3 |
|
Return on Equity (ttm)
|
-343.3 |
|
Qtrly Rev. Growth
|
-12.9 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
2.8 |
|
EBITDA (p.s.)
|
-8.65 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-17 (M) |
|
Levered Free Cash Flow
|
-10 (M) |
Stock Valuations |
|
PE Ratio
|
-0.06 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
4.1 |
|
Price to Sales
|
0.3 |
|
Price to Cash Flow
|
-0.12 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
